Endevica Bio has announced the formation of Abisati, a dedicated spin-off company focused on advancing its promising obesity treatment candidate, 710GO, into clinical development. The new venture aims to initiate Phase I trials in the second half of 2025, marking a significant step forward in the development of alternative weight management therapies.
Promising Preclinical Results
The experimental peptide, which works through the melanocortin system, has shown encouraging results in preclinical studies. In trials with obese monkeys, 710GO demonstrated a 7.5% reduction in body weight over one month compared to control groups. Notably, treated subjects exhibited a consistent 20% decrease in daily caloric intake and showed a preference for healthier, high-fiber, low-fat food options.
Novel Mechanism and Potential Advantages
Russell Potterfield, CEO of both Endevica Bio and Abisati, highlighted the drug's potential advantages: "Our peptide has the potential to help patients lose weight without the side effects such as nausea and vomiting seen with drugs now on the market and without the 'bounce back' weight gain that can happen after patients discontinue medication."
The development of 710GO represents an interesting scientific journey, as its potential for weight management was discovered during research into preventing cachexia-related weight loss. This dual mechanism understanding could provide valuable insights into body weight regulation pathways.
Market Context and Competition
The obesity treatment landscape is currently dominated by GLP-1 receptor agonists, with major players including Novo Nordisk's semaglutide (Wegovy) and Eli Lilly's tirzepatide (Zepbound). Market projections show significant growth potential, with semaglutide expected to generate $42.85 billion in sales by 2030, while tirzepatide is forecasted to reach $57.65 billion.
Therapeutic Landscape Evolution
As 710GO prepares to enter clinical trials, it joins a dynamic therapeutic area where existing treatments are expanding their applications beyond obesity and type 2 diabetes. Recent developments have shown cardiovascular benefits for current market leaders, with Novo Nordisk recently reporting semaglutide's effectiveness in treating metabolic dysfunction-associated steatohepatitis (MASH).
The advancement of 710GO into clinical trials represents a potentially significant addition to the obesity treatment arsenal, particularly if it can deliver on its promise of effective weight management with an improved side effect profile.
